Clinical trials: Allosensitization
End-Stage Kidney Disease
Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers
The purpose of this study is to identify subjects who are highly sensitized with antibodies. It is difficult for these patients to find suitable kidneys.
- Trial name
- NCT00143741
- Testing
- Atorvastatin (Lipitor)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Type 1 Diabetes Mellitus
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.
- Trial name
- NCT01999361
- Testing
- Myfortic
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Rodolfo Alejandro
Allosensitization, Heart Transplant Failure and Rejection
Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation
The purpose of this study is to test whether daratumumab, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting heart transplantation.
- Trial name
- NCT04088903
- Testing
- Daratumumab
- Sponsor
- Ronald Witteles
Kidney Transplantation, Graft Failure
Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy
Graft nephrectomy is associated with massive allo-sensitization following this event. The occurrence of anti-HLA antibodies is a major barrier to perform a second kidney transplantation.
- Trial name
- RAIPONS (NCT04779957)
- Testing
- Tocilizumab
- Where
- France
- Volunteers
- 18 people
- Sponsor
- University Hospital, Toulouse
Allosensitization, Kidney Transplant Rejection
Desensitization in Kidney Allograft Using Daratumumab
Patients highly allosensitized against HLA antigen awaiting for a kidney transplant have less compatible transplants to them, increasing their waitlist time and mortality.
- Conditions
- Allosensitization, Kidney Transplant Rejection, Antibody-mediated Rejection
- Trial name
- DARDAR (NCT04204980)
- Testing
- Daratumumab dose escalation, Daratumumab full dose
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients
Alloantibodies in Pediatric Heart Transplantation
The purpose of this study is to determine the clinical outcomes of sensitized pediatric heart transplant recipients with a positive donor-specific cytotoxicity crossmatch and to compare this group with outcomes in nonsensitized…
- Trial name
- NCT01005316
- Testing
- Induction Therapy, Tacrolimus, Mycophenolate Mofetil
- Where
- 8 sites in United States, Canada
- Volunteers
- 290 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Failure, Allosensitization
Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation
Study to compare once-daily extended release tacrolimus versus twice-daily immediate release tacrolimus following renal allograft failure to reduce the risk of allosensitisation
- Conditions
- Kidney Transplant Failure, Allosensitization, Immunosuppression
- Trial name
- EVITRA (NCT03689075)
- Testing
- Envarsus Oral Product
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- Imperial College Healthcare NHS Trust
End-Stage Renal Disease, Kidney Transplantation
An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens
This study is designed to test the clinical and laboratory observations that suggest IVIG given before and after kidney transplant to patients who are sensitized (highly sensitive) to certain transplant antigens could result in…
- Trial name
- NCT00000935
- Testing
- Intravenous immune globulin (IVIG)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Antibody-mediated Rejection, Allosensitization
Isatuximab in Lung Transplant Recipients
The purpose of this study is to determine the safety and feasibility of adding isatuximab to standard of care therapies in patients who will receive a lung transplant, but have significant antibodies against the donor…
- Trial name
- NCT05862766
- Testing
- Isatuximab, bone marrow biopsy
- Where
- United States
- Sponsor
- NYU Langone Health
Kidney Transplant, Kidney Transplant Failure
Prevent Allosensitization in Patients Who Have Failed a First Renal Transplant (PART)
Kidney transplant is often the best treatment for people with kidney failure, but transplanted kidneys don't always last a lifetime.
- Conditions
- Kidney Transplant, Kidney Transplant Failure, Immunosuppresion
- Trial name
- NCT06802822
- Testing
- Prevention of Allosensitization
- Where
- Canada
- Volunteers
- 96 people
- Sponsor
- University of British Columbia
Allosensitization, Heart Transplant Failure and Rejection
Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation
The purpose of this study is to test whether Daratumumab-SC, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting heart transplantation.
- Trial name
- NCT04610320
- Testing
- Daratumumab-SC
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ronald Witteles